Epigenetic mechanisms in AML - a target for therapy.
Oki
Yasuhiro
Y
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Issa
Jean-Pierre J
JP
D000107:Acetylation / Q000187:drug effects; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors / Q000502:physiology; D019175:DNA Methylation / Q000187:drug effects; D016503:Drug Delivery Systems; D044127:Epigenesis, Genetic / Q000187:drug effects; D015973:Gene Expression Regulation, Leukemic / Q000235:genetics*; D020868:Gene Silencing / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006657:Histones / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008745:Methylation / Q000187:drug effects; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology; D011499:Protein Processing, Post-Translational / Q000187:drug effects
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D009363:Neoplasm Proteins; D004248:DNA (Cytosine-5-)-Methyltransferases